Patent and Tech Transfer Sessions at 2013 BIO International Convention

Patently BIOtech

Patent and Technology Transfer sessions feature prominently at the 2013 BIO International Convention in Chicago from April 22-25, 2013. Topics cover developing patent and tech transfer issues in the U.S. and internationally. Many of the sessions provide Continuing Legal Education (CLE) and Registered Technology Transfer Professional (RTTP) credits. The Biotech Patenting and Technology Transfer Track sessions are below:

Behind the Tech Transfer Headlines: What are You Missing?

Headline-making news reports of multiyear, multimillion dollar strategic alliances demonstrate that university entrepreneurs are keen to pursue technology transfer and partner with industry. These partnerships – whether exclusive arrangements or part of pre-competitive consortiums – can kick-start the process, secure intellectual property and gain thought-leader expertise. The rightsizing of internal research often means an increase in early stage partnering with academia. Creating strong relationships between industry and academia leads to effective commercialization of novel technologies, while helping replenish Pharma’s R&D pipeline. Explore some recent examples of partnerships between industry and academic research centers including Novartis and University of Pennsylvania, University of Virginia and AstraZeneca, AstraZeneca and Weill Cornell Medical College, and Pfizer and Gilead

Trends in Biotech IP Law in Canada

Former USPTO Director Kappos will moderate panelists discussing recent patent developments in Canada including patent utility and their implications for innovative biotech companies. Speakers represent the Canadian R&D and Generic industries as well as other foreign jurisdictions.

The Unitary Patent: How Will it Affect the Biotech Sector and Your Business?

The EU Council decision to establish a unitary patent system for 25 countries paves the way for a Pan-European patent system – something that has been eagerly awaited by industry. Unitary patents will be valid across the participating countries and patent litigations will be handled by a centralized patent court system located in Paris with branches in London and Munich. These new developments will dramatically reshape the business landscape within Europe and have a tremendous impact on patent strategies of applicants, especially in the biotech sector. What changes are ahead and what are the expected benefits? Come and find out.

Multi-Party and Cross-Border Patent Issues Affecting Biotech Businesses

Recent developments in U.S. case law may dramatically affect an innovator’s ability to protect technologies that competitors may seek to copy and divide among multiple parties and/or in multiple countries. An international panel of experienced IP professionals with backgrounds in biopharma and devices will discuss challenges and solutions for protecting and enforcing patents in the U.S. and overseas, including the types of biotechnology innovations for which multi-party and multi-jurisdiction enforcement issues are likely to arise and the state of the law concerning these issues. Panelists will also discuss the potential impact on the enforcement of biotechnology IP, protection of innovations and the impact of recent legislation (e.g., the America Invents Act).

Myriad, Mayo, and Beyond: Developments in the Law of Patentable Subject Matter

The question of what products and processes are eligible for patent protection, and in particular the scope of the exception for laws of nature, has been the subject of recent scrutiny in the Supreme Court and Federal Circuit. The panel will address the latest developments in patentable subject matter law regarding the patenting of isolated DNA molecules. Panelists will present recent case examples such as the Myriad Genetics case, Mayo Collaborative Services vs. Prometheus Labs., Inc. case, and related developments in the courts and Congress that could affect the biotechnology industry.

The Compulsory Licensing Trend: Increased Access, or Lost Opportunities and Unintended Consequences?

Although there are a full range of tools available to countries who wish to increase access to healthcare, compulsory licensing has been described by some as the preferential tool for access. Increasingly countries are looking to compulsory licensing as a tool to gain access to medicines where no public health emergency or similar circumstances exist. A panel of experts will look at various approaches and considerations related to increasing access to medicines, including compulsory licensing. The panel will also look at the economic, investment and access consequences of using compulsory licenses, including countries that have and have not made use of this option as examples.

Emerging Markets Heads of Patent Offices Discussion

Patent Office Directors in emerging and newly-industrialized countries have unique opportunities to use Patent Office initiatives to foster domestic biotechnology innovation. This panel will discuss initiatives to stimulate both domestic and international innovation across all biotechnology sectors. The Directors will also discuss political and social considerations when leveraging the patent system to foster biotechnology innovation. Comparing practices across markets should provide attendees with a better understanding of both the opportunities and challenges they may face in each of these markets.

IP Strategies for the Developing World

Developing countries are considered the fastest growing markets for health care, but many countries have poor or inconsistent systems in place for protecting the intellectual property of innovators. This can be a barrier to commercializing and providing access to medical innovation in these markets. How do you protect inventions? This panel will outline strategies that both for-profit and non-profit groups are taking to prepare for the globalization of their innovative products.

The Morning After!: What to do in U.S. & European Patent Prosecution Following the Enactment of AIA

The America Invents Act (AIA) is fully enacted leaving the U.S. with two patent systems: old law (pre-March 16, 2013) and new law (March 16, 2013 and thereafter). The final version of the First Inventor to File (FITF) USPTO Rules has been implemented and the USPTO has done its first pass on examiner training on the new rules. This session discusses how best to proceed in the parallel “first-to-invent” and “first-inventor-to-file” patent systems of the U.S. from the perspectives of the USPTO and industry representatives. It will also give the European perspective on patenting from a Director at the European Patent Office (EPO), with an emphasis on similarities and differences between the European Patent Convention and the AIA, including the benefits of filings with both the USPTO and the EPO. Thus, this session will educate on what to do now in U.S. and European patent prosecution, from those on the forefront of biotech patenting.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>